Investment Rating - The report maintains a "Buy" rating for the company, with a target price not specified [7]. Core Insights - The company has shown a recovery with consecutive quarters of revenue and profit growth, indicating a potential exit from a low economic cycle [2][5]. - The new catalyst products have achieved breakthroughs, expanding the company's market space in the basic chemical sector [4]. - The company is expected to launch its hydrogenated nitrile butadiene rubber (HNBR) project in the second half of 2025, which will enhance its market offerings [5]. Financial Performance - In 2024, the company reported a revenue of 1.687 billion yuan, a decrease of 5.5% year-on-year, and a net profit of 93 million yuan, down 17.95% year-on-year [1]. - The fourth quarter of 2024 saw a revenue increase of 22% year-on-year and a net profit increase of 88.3% year-on-year [1][2]. - The first quarter of 2025 achieved a revenue of 626 million yuan, a 105.3% increase year-on-year, and a net profit of 22 million yuan, up 90.5% year-on-year [1][2]. Sales and Market Performance - The company reported a historical high in catalyst sales, with total sales reaching 597 tons, a year-on-year increase of 60.21% [3]. - Sales in the pharmaceutical sector increased by 71.79%, while sales in the new chemical materials sector surged by 173.82% [3]. Product Development - The company has focused on innovation, leading to the successful launch of new catalyst products, including various types for basic chemicals and environmental applications [4]. - The HNBR project is anticipated to broaden the application scenarios and market space for HNBR, providing domestic supply for downstream industries [5]. Financial Projections - The company forecasts net profits of 191 million yuan, 242 million yuan, and 321 million yuan for 2025, 2026, and 2027, respectively, indicating a strong recovery trajectory [5].
凯立新材(688269):连续两个季度收入利润双增,化工新催化剂实现突破